Comparative analysis of carmellose 0.5% versus hyaluronate 0.15% in dry eye: A flow cytometric study

Cornea

Volumn 29, Issue 2, 2010, Pages 167-171

  Sanchez, Miguel Angel ^a   Torralbo Jimenez, Pilar ^b   Giron, Natalia ^c   De La Heras, Beatriz ^c   Herrero Vanrell, Rocio ^c   Arriola Villalobos, Pedro ^a   Diaz Valle, David ^a   Alvarez Barrientos, Alberto ^b   Benitez Del Castillo, Jose M ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b Cytomics Unit   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Carmellose; Flow cytometric; Hyaluronate; Impression cytology; Inflammatory markers

Indexed keywords

CARBOXYMETHYLCELLULOSE; CD11B ANTIGEN; CD3 ANTIGEN; FLUORESCEIN; HLA DR ANTIGEN; HYALURONIC ACID; LUBRISTIL; UNCLASSIFIED DRUG; VISCOFRESH;

ABSENCE OF SIDE EFFECTS; ADULT; ANESTHESIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA; CYTOLOGY; DRUG SAFETY; DRY EYE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; LACRIMAL DUCT; MALE; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIRMER TEST;

ADULT; AGED; ANTIGENS, CD11B; ANTIGENS, CD3; BIOLOGICAL MARKERS; CARBOXYMETHYLCELLULOSE; CORNEA; DOUBLE-BLIND METHOD; DRY EYE SYNDROMES; FEMALE; FLOW CYTOMETRY; FLUORESCEIN; HLA-DR ANTIGENS; HUMANS; HYALURONIC ACID; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROGNOSIS; STAINING AND LABELING; TEARS;

EID: 77649121083     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181b11648     Document Type: Article

References (19)

1. Schein OD, Munoz B, Tielsch JM, et al. Prevalence of dry eye among elderly. Am J Ophthalmology. 1997;124:723-728.
2. Baudouin C, Haouat N, Brignole F, et al. Immunopathological findings in conjunctival cells using immunofluorescence staining of impression cytology specimens. Br J Ophthalmol. 1992;76:545-549.
3. Mircheff AK, Wood RL, Gierow JP. Traffic of major histocompatibility complex class II molecules in rabbit lacrimal gland acinar cells. Invest Ophthalmol Vis Sci. 1994;35:3943-3953.
4. Tsubota K, Fukagawa K, Fujihara T, et al. Regulation of human leukocyte antigen expression in human conjunctival epithelium. Invest Ophthalmol Vis Sci. 1999;40:28-34.
5. Damato BE, Allan D, Murray SB, et al. Senile atrophy of the human lachrymal gland: the contribution of chronic inflammatory disease. Br J Ophthalmol. 1984;68:674-680.
6. Baudouin C, Brignole F, Becquet F, et al. Flow cytometry in impression cytology specimens: a new method for evaluation of conjunctival inflammation. Invest Ophthalmol Vis Sci. 1997;8:1458-1464.
7. Stern ME, Beuerman RW, Fox RL, et al. The pathology of dry eye: the interaction between the ocular surface and lachrymal glands. Cornea. 1998;17:584-589.
8. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5:75-92.
9. Brignole-Baudouin F, Ott AC, Warnet JM, et al. Flow cytometry in conjunctival impression cytology: a new tool for exploring ocular surface pathologies. Exp Eye Res. 2004;78:473-481.
10. Fujihara T, Takeuchi T, Saito K, et al. Evaluation of human conjunctival epithelium by a combiantion of brush cytology and flow cytometry: an approach to the quantitative technique. Diagn Cytopathol. 1997;17:456-460.
11. Brignole F, de Saint-Jean M, Goldschild M, et al. Expression of Fas-Fas ligand antigens and apoptotic marker APO2-7 by the human conjunctival epithelium. Positive correlation with class II HLA-DR expression in inflammatory ocular surface disorders. Exp Eye Res. 1998;67: 687-697.
12. Pisella PJ, Brignole F, Debbasch C, et al. Flow cytometric analysis of conjunctival epithelium in occular rosacea and keratoconjunctivitis sicca. Ophthalmology. 2000;107:1841-1849.
13. Brignole F, Pisella PJ, De Saint Jean M, et al. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Invest Ophthalmol Vis Sci. 2001;112:1446-1454.
14. Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003;22:640-650.
15. Vico E, Ben?́tez del Castillo JM, Giménez RA, et al. Tear function index validation for dry eye diagnosis. Arch Soc Esp Oftalmol. 2004;79:265-271.
16. Brignole F, Pisella PJ, Dupas B, et al. Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis. Graefe's Arch Clin Exp Ophthalmol. 2005;243:531-538.
17. Shimmura S, Ono M, Shinozaki K, et al. Sodium hyaluronate eye drops in the treatment of dry eyes. Br J Ophthalmol. 1995;79:1007-1011.
18. Sand BB, Marner K, Norn MS. Sodium hyaluronate in the treatment of keratoconjunctivitis sicca. A double masked clinical trial. Acta Ophthalmol Scand. 1989;67:181-183.
19. Corrales RM, Diebold Y, Callejo S, et al. In vitro toxicity of non-preserved artificial-tear formulations. Arch Soc Esp Oftalmol. 2001;76:613-619.